In short
Clinical trials are investigating HLX43 in people with advanced non-small cell lung cancer (NSCLC). These studies aim to evaluate how well it works and how safe it is, especially in adults with advanced disease. The main trial listed is a Phase 2 study.
Key points
- Clinical trials are studying HLX43 in advanced non-small cell lung cancer (NSCLC). The listed study is a Phase 2, interventional trial that has been authorised and plans to enroll 243 people. The main goal is to evaluate clinical efficacy, with objective response rate as the primary outcome. This means the study is checking how many patients have a measurable tumor response on scans. The trial uses blinded independent central review and RECIST v1.1, which are standard ways to assess cancer changes.
Trial overview
The listed study is a clinical trial of HLX43 in people with advanced non-small cell lung cancer (NSCLC). It is an interventional study, which means researchers give the study treatment and then measure what happens.
The trial title says it is a global safety and effectiveness study, and the brief summary says it aims to evaluate the clinical efficacy of HLX43 in advanced NSCLC.
Who the study is for
This trial is for people with advanced non-small cell lung cancer (NSCLC). The source data does not list more detailed entry rules, such as age limits or prior treatments, so those details are not available here.
The study plans to enroll 243 participants, which means up to 243 people are expected to join if they meet the study rules.
What the study measures
The main outcome is objective response rate (ORR). ORR shows how many people have a measurable cancer response, such as the tumor getting smaller, based on scan review.
The study uses Blinded Independent Central Review (BICR) and RECIST v1.1 to assess the response. BICR means independent reviewers look at the scans without knowing which treatment was given, and RECIST v1.1 is a standard system for measuring tumor changes.
Trial phase and design
The study is in Phase 2. Phase 2 trials usually focus on whether a treatment may work in a specific disease while continuing to collect safety information.
The trial status is listed as Authorised. This means the study has been approved to proceed according to the source data.
The intervention is listed as HLX43 for Injection given by intravenous administration, which means it is given through a vein.
What the results may mean
This trial is designed to show whether HLX43 can produce a measurable cancer response in advanced NSCLC. Because the study is still in Phase 2, it is part of the process of learning more about the treatment in a defined patient group.
The available data does not report study results yet, so the article can only describe the trial plan, not the outcome.